The Human Variable 

Here I apply CYNAERA’s analytical framework to the unlikely case of a consumer snack, Frito-Lay’s Baked Lay’s, as an emergent functional-nutrition platform for dysautonomia and MCAS patients. Using CYNAERA’s prevalence modeling (US-CCUC™, S³™, Pathos™, SymCas™, BRAGS™) and global market-behavior analytics, I examine how a legacy brand could reposition a common product into a precision-nutrition solution. A $3 billion opportunity in plain sight.

The CYNAERA Primary Chronic Trigger (PCT) framework embeds PEM as a probability-weighted conversion event inside a prevalence model that accounts for viral exposure, environmental load, climate volatility, and recovery suppression. Modeled remission rises from historical 12–18 percent toward 35–50 percent under PEM-aware, terrain-timed designs, with early-intervention subsets reaching 42–60 percent in best-case conditions.

Introduction Myalgic encephalomyelitis/chronic fatigue syndrome is common, costly, and routinely missed until someone reads the chart as a timeline. Patients describe a delayed crash after effort that lasts days to weeks. CDC and NICE name this pattern post-exertional malaise and make it central to diagnosis (CDC, 2024; NICE NG206, 2021). Yet most people with ME/CFS still do not have a diagnosis, and many wait years for recognition, with the National Academies reporting both

Innovative Orthostatic Intolerance & POTS Detection for Faster Diagnosis. Orthostatic intolerance and POTS are increasingly more common, disabling, and often missed until someone reads the chart as a timeline. The signs of these conditions already lives in routine positions and vitals clinicians collect anyway: triage after upright waiting, first supine on the bed, a short bathroom walk and return, and discharge.

STAIR is a structured method for helping hypersensitive patients safely prepare for new exposures: medications, supplements, clinical trials, or even food reintroductions. It’s designed specifically for bodies that traditional medicine excludes, the “too sensitive,” the “too complex,” the “we don’t know what to do with you.”

Contrary to the conventional framing of remission as spontaneous or unachievable, this framework presents remission as a predictable biological outcome, emerging from synchronized interventions across immune, hormonal, mitochondrial, and environmental axes. The CYNAERA Remission Pathway™ outlines a five-phase stabilization and recovery model, while the STAIR: Stable Method™ offers pre-intervention protection for hypersensitive subgroups, including those with mast cell reacti